Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD

Blood Adv. 2019 Jan 22;3(2):184-186. doi: 10.1182/bloodadvances.2018028282.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Drug Resistance
  • Follow-Up Studies
  • Graft vs Host Disease / diagnosis
  • Graft vs Host Disease / drug therapy*
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / mortality
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Kaplan-Meier Estimate
  • Multicenter Studies as Topic
  • Randomized Controlled Trials as Topic
  • Steroids / therapeutic use
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Steroids
  • inolimomab